Related Experiment Video
Updated: Jul 11, 2026

11:12
Hyperinsulinemic-Euglycemic Clamp in the Conscious Rat
Published on: February 8, 2011
Glucagon metabolism in the rat
The Journal of Clinical Investigation
|July 1, 1978
Summary
Kidney disease significantly reduces glucagon clearance in rats. Even without filtration, kidneys extract glucagon, indicating uptake occurs post-glomerularly, impacting overall hormone metabolism.
Area of Science:
- Nephrology
- Endocrinology
- Metabolism
Background:
- The kidney plays a role in the metabolic clearance of hormones.
- Glucagon is a key hormone in glucose regulation.
- Understanding renal handling of glucagon is crucial for metabolic studies.
Purpose of the Study:
- To investigate the renal handling of biologically active glucagon (immunoreactive glucagon [IRG]).
- To determine the kidney's contribution to the peripheral metabolism of glucagon.
- To compare glucagon handling in normal and uremic rat models.
Main Methods:
- Studied normal and uremic rat models (partially nephrectomized, bilaterally ureteral ligated, bilaterally nephrectomized).
- Measured metabolic clearance rate (MCR) of glucagon.
- Assessed renal extraction of endogenous and exogenous glucagon.
- Analyzed glucagon uptake in relation to filtered load and glomerular filtration.
Main Results:
- Glucagon MCR was reduced by approximately one-third in all uremic rat groups compared to normal rats.
- In normal rats, the kidney accounted for 30% of glucagon's overall metabolic clearance.
- Renal glucagon extraction occurred even in the absence of glomerular filtration, suggesting post-glomerular uptake.
Conclusions:
- Renal function significantly impacts glucagon metabolic clearance.
- The kidney contributes substantially to glucagon catabolism.
- Glucagon uptake by the kidney involves both filtration/reabsorption and post-glomerular capillary mechanisms.
Related Concept Videos
Hormones Regulating Blood Glucose
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
Glucose Homeostasis: Regulation of Blood Glucose
Carbohydrates consumed through foods are converted into glucose, a crucial energy source for the body. In the prandial state, high blood glucose levels stimulate the secretion of insulin from the pancreas. Insulin inhibits hepatic glucose production and stimulates glucose uptake and metabolism by muscle and adipose tissue. The excess glucose is converted into glycogen and stored in the liver and muscles.
During fasting, when blood glucose levels are low, the pancreas secretes glucagon. it...
During fasting, when blood glucose levels are low, the pancreas secretes glucagon. it...
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are co-secreted in...
Insulin and C-peptide are co-secreted in...
Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Hypoglycemia and Glucagon
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...

